Bausch + Lomb Corporation (BLCO) AI Stock Analysis

Bausch + Lomb Corporation operates internationally across three primary segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. Vision Care provides contact lenses, contact lens care products, over-the-counter eye drops, and nutritional supplements for conditions like allergies and dry eye. The Ophthalmic Pharmaceuticals segment develops and distributes proprietary and generic pharmaceuticals for ocular conditions, post-operative care, and therapeutic lenses. The Surgical division produces tools, intraocular lenses, phacoemulsification equipment, and instruments for cataract, vitreous, and retinal procedures. Headquartered in Vaughan, Canada, the company was established in 1853 and operates as a subsidiary of Bausch Health Companies Inc.

Revenue increased from $3.77B in FY2021 to $5.10B in FY2025, reflecting a 5-year revenue CAGR of 8.4%. Gross margin contracted from 61.0% in FY2021 to 54.8% in FY2025, while operating margin fell from 8.7% to 3.7% over the same period. Net income moved from $182.0M in FY2021 to -$360.0M in FY2025, marking three consecutive annual net losses. Over the trailing twelve months, revenue reached $5.32B with a profit margin of -3.2% and an operating margin of 7.8%. For the latest quarter ended June 30, 2026, quarterly revenue grew 9.1% year-over-year, while quarterly earnings declined 88.6%.

As of June 30, 2026, Bausch + Lomb held $367.0M in cash and short-term investments against $5.12B in total debt, resulting in net debt of $4.75B. The debt-to-equity ratio stood at 0.80, and the current ratio was 1.55 against shareholders' equity of $6.38B. Operating cash flow improved to $283.0M in FY2025 from -$17.0M in FY2023, but free cash flow remained negative at -$66.0M due to $349.0M in capital expenditures. Share count increased 2.0% over five years.

BLCO trades at a forward P/E of 11.4x, below the 17.3x forward P/E median of its US-listed Healthcare peers. Its price-to-sales ratio is 1.1x compared to the peer median of 4.1x, while its EV-to-EBITDA multiple of 14.8x is above the peer median of 12.0x. Over the past year, the stock returned 11.0%, trailing the 16.8% return of the S&P 500.

Wall Street coverage includes 5 Strong Buy, 2 Buy, 7 Hold, and 1 Sell ratings. The mean price target of $19.39 suggests a 17.6% upside compared to the last close of $16.49. For the current fiscal year ending December 31, 2026, consensus estimates project EPS of $0.81 on revenue of $5.49B. For the next fiscal year, 14 analysts expect EPS of $1.11 on revenue of $5.82B. The company beat EPS estimates in 2 of the last 4 quarters, and the next earnings date is October 28, 2026.

This page is an AI-written research summary of Bausch + Lomb Corporation (BLCO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BLCO income statement, BLCO balance sheet, BLCO key metrics, BLCO analyst forecast, BLCO chart. See the BLCO stock overview for the latest quote and news.